Observational study on the therapeutic management and economic burden of adult patients with moderate to severe plaque psoriasis in France – the POP study

References

• Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–11. doi: 10.1111/jdv.13854
   PubMed Web of Science ®Google Scholar
• Grodner C, Mezzarobba M, Weill A, et al. Evolution of topical steroids consumption before and after initiation of systemic treatment in psoriasis: epidemiologic study in a real-world analysis of the French national health insurance database. J Eur Acad Dermatol Venereol JEADV. 2020;34(6):e259–62. doi: 10.1111/jdv.16238
   PubMed Web of Science ®Google Scholar
• Richard M-A, Corgibet F, Beylot-Barry M, et al. Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the OBJECTIFS PEAU study. J Eur Acad Dermatol Venereol JEADV. 2018;32(11):1967–1971. doi: 10.1111/jdv.14959
   PubMed Web of Science ®Google Scholar
• Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population‐based study. Arthritis Care Res. 2009;61(2):233–239. doi: 10.1002/art.24172
   Web of Science ®Google Scholar
• Iskandar IYK. Disease burden and quality of life in patients with moderate-to-severe psoriasis stratified according to previous systemic treatment exposure. J Eur Acad Dermatol Venereol. 2020;34(11):2454–2455. doi: 10.1111/jdv.16971
   PubMed Web of Science ®Google Scholar
• Singh S, Taylor C, Kornmehl H, et al. Psoriasis and suicidality: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(3):425–440.e2. doi: 10.1016/j.jaad.2017.05.019
   PubMed Web of Science ®Google Scholar
• Liu L, Lin N-X, Yu Y-T, et al. Epidemiology of mental health comorbidity in patients with psoriasis: an analysis of trends from 1986 to 2019. Psychiatry Res. 2023;321:115078. doi: 10.1016/j.psychres.2023.115078
   PubMed Web of Science ®Google Scholar
• Van Beugen S, Schut C, Kupfer J, et al. Perceived stigmatization among dermatological outpatients compared with controls: an observational multicentre study in 17 European countries. Acta Derm Venereol. 2023;103:6485. doi: 10.2340/actadv.v103.6485
   PubMed Web of Science ®Google Scholar
• Koo J, Marangell LB, Nakamura M, et al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol JEADV. 2017;31(12):1999–2009. doi: 10.1111/jdv.14460
   PubMed Web of Science ®Google Scholar
• Amatore F, Villani A-P, Tauber M, et al. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol JEADV. 2019;33(3):464–483. doi: 10.1111/jdv.15340
   PubMed Web of Science ®Google Scholar
• Meyer N, Paul C, Feneron D, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol JEADV. 2010;24:1075–1082. doi: 10.1111/j.1468-3083.2010.03600.x
   PubMed Web of Science ®Google Scholar
• Richard M‐, Paul C, De Pouvourville G, et al. Out‐of‐pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross‐sectional, non‐comparative, multicentre study. J Eur Acad Dermatol Venereol. 2021;35(4):912–918. doi: 10.1111/jdv.17000
   PubMed Web of Science ®Google Scholar
• Le Moigne M, Sommet A, Lapeyre-Mestre M, et al. Healthcare cost impact of biological drugs compared with traditional systemic treatments in psoriasis: a cohort analysis in the French insurance database. J Eur Acad Dermatol Venereol JEADV. 2014;28(9):1235–1244. doi: 10.1111/jdv.12318
   PubMed Web of Science ®Google Scholar
• Tuppin P, de Roquefeuil L, Weill A, et al. French national health insurance information system and the permanent beneficiaries sample. Revue d’Épidémiologie et de Santé Publique. 2010;58(4):286–290. doi: 10.1016/j.respe.2010.04.005
   PubMed Web of Science ®Google Scholar
• Sbidian E, Mezzarobba M, Weill A, et al. Persistence of treatment with biologics for patients with psoriasis: a real‐world analysis of 16 545 biologic‐naïve patients from the French National health Insurance database (SNIIRAM). Br J Dermatol. 2019;180(1):86–93. doi: 10.1111/bjd.16809
   PubMed Web of Science ®Google Scholar
• INSEE. Indice des prix à la consommation - Base 2015 - Ensemble des ménages - France- Ensemble hors tabac. cited 2022 Mar 22. Available from: https://www.insee.fr/fr/statistiques/serie/001763852#Documentation
   Google Scholar
• Chouaïd C, Grumberg V, Batisse A, et al. Machine learning–based analysis of treatment sequences typology in advanced non–small-Cell lung Cancer long-term survivors treated with nivolumab. JCO Clin Cancer Inform. 2022;6(6):11. doi: 10.1200/CCI.21.00108
   Google Scholar
• Pina Vegas L, Penso L, Claudepierre P, et al. Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French health Insurance database. JAMA Dermatol. 2022;158(5):513–522. doi: 10.1001/jamadermatol.2022.0364
   PubMed Web of Science ®Google Scholar
• Curmin R, Guillo S, De Rycke Y, et al. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ. J Eur Acad Dermatol Venereol JEADV. 2022;36(11):2101–2112. doi: 10.1111/jdv.18409
   PubMed Web of Science ®Google Scholar
• Haute autorité de santé. Rapport d’évaluation des médicaments biologiques du psoriasis en plaque de l’adulte inclus dans l’étude PSOBIOTEQ 1 - Résultats intermédiaires à 3 ans de l’étude PSOBIOTEQ 1. HAS; 2021.
   Google Scholar
• Sbidian E, Mezzarobba M, Shourick J, et al. Choice of systemic drugs for the management of moderate-to-severe psoriasis: a cross-country Comparison based on National health Insurance data. Acta Derm Venereol. 2021;101(6):adv00473. doi: 10.2340/00015555-3765
   PubMedGoogle Scholar
• Villani AP, Amatore F, Tauber M, et al. Impact of the French guidelines on the prescribing habits of systemic treatments for moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2020;34(11):e747–8. doi: 10.1111/jdv.16601
   PubMed Web of Science ®Google Scholar
• Villacorta R, Teeple A, Lee S, et al. A multinational assessment of work‐related productivity loss and indirect costs from a survey of patients with psoriasis. Br J Dermatol. 2020;183(3):548–558. doi: 10.1111/bjd.18798
   PubMed Web of Science ®Google Scholar
• Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: From the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev DÉpidémiologie Santé Publique. 2017;65:S149–67. doi: 10.1016/j.respe.2017.05.004
   PubMed Web of Science ®Google Scholar
• Dieleman J, Campbell M, Chapin A, et al. Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. Lancet. 2017;389(10083):1981–2004. doi: 10.1016/S0140-6736(17)30874-7
   PubMed Web of Science ®Google Scholar
• Centre des liaisons européennes et internationales de sécurité sociale, République Française. The French Social Security System. I-Health, maternity, paternity, disability, and death. Vous informer sur la protection sociale à l’international 2020. Accessed 2020 Oct 12. Availabe from: https://www.cleiss.fr/docs/regimes/regime_france/an_1.html
   Google Scholar
• Chevreul K, Berg Brigham K, Durand-Zaleski I, et al. France: health System review. Health Syst Transit. 2015;17(3): 1–218, xvii.
   PubMedGoogle Scholar
• Assurance Maladie. Tableaux récapitulatifs des taux de remboursement. Ameli.Fr. 2022 Mar 4. https://www.ameli.fr/rhone/assure/remboursements/rembourse/tableau-recapitulatif-taux-remboursement
   Google Scholar